QLS1317 for Advanced Cancers With Specific Genetic Changes
Part of Cancer clinical trials.
This study tests a new drug called QLS1317 in patients with advanced solid tumors that have specific genetic changes (MSI-H or dMMR) and haven't responded to standard treatments. The goal is to see if QLS1317 can shrink these tumors and is safe to use.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- Your doctor expects you to live at least 3 more months
- You have an advanced solid tumor with MSI-H or dMMR genetic changes that didn't respond to standard treatment
- You have at least one tumor that can be measured on imaging scans
- You are in good enough health to receive treatment (ECOG score 0–1, meaning you can do most normal activities)
- Your organs (liver, kidneys, heart, etc.) are working well enough for the study drug
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called QLS5133 for people with advanced solid tumors that have not responded to other treatments. The drug is given alone, and the study aims to see if it is safe and effective.
This study tests a new experimental drug called QLS5316 for people with advanced solid tumors that have not responded to standard treatments. The drug works like a 'smart bomb'—it seeks out and delivers medicine directly to cancer cells.
This trial tests a new drug, QLS5132, for people with advanced solid tumors that have not responded to other treatments. The goal is to see if the drug is safe and effective.
This trial tests an experimental drug, QLS-1304, for people with advanced solid tumors that have stopped responding to standard treatment. The goal is to see if the drug is safe and effective.
This trial tests a new drug called QLS5212 in people with solid tumors that have spread or cannot be removed by surgery. The goal is to see if the drug is safe and effective.
This trial tests an experimental drug, QLS1209, for people with advanced solid tumors that have specific genetic changes (CCNE1 amplification, FBXW7 mutation, or PPP2R1A mutation). It aims to see if the drug is safe and effective for those who have not responded to standard treatments or have no standard options.
Hear when a new MSI-H or dMMR Advanced Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.